Literature DB >> 26137031

Expression of a-disintegrin and metalloproteinase 10 correlates with grade of malignancy in human glioma.

Min Qu1, B O Qiu2, Wende Xiong1, Dong Chen1, Anhua Wu2.   

Abstract

The aim of the present study was to determine the expression of a-disintegrin and metalloproteinase 10 (ADAM10) in human glioma tissues from surgical specimens and discuss its possible significance in glioma biology. A total of 43 glioma specimens obtained from patients between 2007 and 2010 were collected and a series of assays were performed. Of these, 22 cases were low-grade gliomas, while 21 cases were high-grade gliomas. In addition, 20 cases of meningioma were used as the control group. Reverse transcription-polymerase chain reaction (RT-PCR), western blot analysis and immunohistochemistry were used to determine the mRNA and protein expression levels of ADAM10. Besides the quantitative analysis, histological observations were also performed to localize ADAM10 expression in glioma cells. The RT-PCR and western blot analysis results demonstrated increased ADAM10 expression in the low-grade glioma samples compared with the control (P<0.05), while ADAM10 expression was further increased in the high-grade glioma samples (P<0.01 vs. control; P<0.05 vs. low-grade glioma), indicating that the mRNA and protein expression levels of ADAM10 were malignancy-dependent. The immunohistochemical analysis revealed that the ADAM10 protein was located on both the tumor cell membrane and blood vessel walls within tumor tissues. In conclusion, these results indicated that ADAM10 expression correlates with the grade of malignancy in human glioma from surgical specimens. In addition, the fact that ADAM10 protein was expressed on cell membranes and blood vessel walls within tumor tissues, indicates that its expression may be associated with invasive tumor growth and peritumoral edema formation.

Entities:  

Keywords:  a-disintegrin and metalloprotease 10; expression; glioma; malignancy

Year:  2015        PMID: 26137031      PMCID: PMC4467264          DOI: 10.3892/ol.2015.2993

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  35 in total

Review 1.  Extracellular matrix remodelling: the role of matrix metalloproteinases.

Authors:  Ivan Stamenkovic
Journal:  J Pathol       Date:  2003-07       Impact factor: 7.996

Review 2.  Shedding light on ADAM metalloproteinases.

Authors:  Ari-Pekka J Huovila; Anthony J Turner; Markku Pelto-Huikko; Iivari Kärkkäinen; Rebekka M Ortiz
Journal:  Trends Biochem Sci       Date:  2005-07       Impact factor: 13.807

3.  ADAMs (a disintegrin and metalloproteinase) messenger RNA expression in Helicobacter pylori-infected, normal, and neoplastic gastric mucosa.

Authors:  Tetsuro Yoshimura; Toshihiko Tomita; Michael F Dixon; Anthony T R Axon; Philip A Robinson; Jean E Crabtree
Journal:  J Infect Dis       Date:  2002-01-17       Impact factor: 5.226

4.  Metalloproteinase disintegrins ADAM8 and ADAM19 are highly regulated in human primary brain tumors and their expression levels and activities are associated with invasiveness.

Authors:  Dirk Wildeboer; Silvia Naus; Qing-Xiang Amy Sang; Jörg W Bartsch; Axel Pagenstecher
Journal:  J Neuropathol Exp Neurol       Date:  2006-05       Impact factor: 3.685

5.  A disintegrin and metalloprotease (ADAM)10 is highly expressed in hepatocellular carcinoma and is associated with tumour progression.

Authors:  Wei Zhang; Songyang Liu; Kuai Liu; Yingchao Wang; Bai Ji; Xuechun Zhang; Yahui Liu
Journal:  J Int Med Res       Date:  2014-03-26       Impact factor: 1.671

Review 6.  The WHO classification of tumors of the nervous system.

Authors:  Paul Kleihues; David N Louis; Bernd W Scheithauer; Lucy B Rorke; Guido Reifenberger; Peter C Burger; Webster K Cavenee
Journal:  J Neuropathol Exp Neurol       Date:  2002-03       Impact factor: 3.685

7.  Photodynamic therapy of brain tumours: evaluation of porphyrin uptake versus clinical outcome.

Authors:  Stanley S Stylli; Megan Howes; Lachlan MacGregor; Priya Rajendra; Andrew H Kaye
Journal:  J Clin Neurosci       Date:  2004-08       Impact factor: 1.961

Review 8.  Biology of glioma cancer stem cells.

Authors:  Deric M Park; Jeremy N Rich
Journal:  Mol Cells       Date:  2009-07-20       Impact factor: 5.034

9.  ADAM10 overexpression confers resistance to doxorubicin-induced apoptosis in hepatocellular carcinoma.

Authors:  Cheng-lin Yang; Feng-qin Jiang; Feng Xu; Gui-xing Jiang
Journal:  Tumour Biol       Date:  2012-05-13

10.  TRAIL and paclitaxel synergize to kill U87 cells and U87-derived stem-like cells in vitro.

Authors:  Bo Qiu; Xiyang Sun; Dongyong Zhang; Yong Wang; Jun Tao; Shaowu Ou
Journal:  Int J Mol Sci       Date:  2012-07-20       Impact factor: 6.208

View more
  7 in total

1.  Proteome and Secretome Characterization of Glioblastoma-Derived Neural Stem Cells.

Authors:  Satoshi Okawa; Sladjana Gagrica; Carla Blin; Christine Ender; Steven M Pollard; Jeroen Krijgsveld
Journal:  Stem Cells       Date:  2016-12-04       Impact factor: 6.277

2.  Preferential Antibody and Drug Conjugate Targeting of the ADAM10 Metalloprotease in Tumours.

Authors:  Hengkang Yan; Mary E Vail; Linda Hii; Nancy Guo; Paul J McMurrick; Karen Oliva; Simon Wilkins; Nayanendu Saha; Dimitar B Nikolov; Fook-Thean Lee; Andrew M Scott; Peter W Janes
Journal:  Cancers (Basel)       Date:  2022-06-28       Impact factor: 6.575

3.  Targeting neuronal activity-regulated neuroligin-3 dependency in high-grade glioma.

Authors:  Humsa S Venkatesh; Lydia T Tam; Pamelyn J Woo; James Lennon; Surya Nagaraja; Shawn M Gillespie; Jing Ni; Damien Y Duveau; Patrick J Morris; Jean J Zhao; Craig J Thomas; Michelle Monje
Journal:  Nature       Date:  2017-09-20       Impact factor: 49.962

4.  Impact of mesenchymal stem cells' secretome on glioblastoma pathophysiology.

Authors:  Joana Vieira de Castro; Eduardo D Gomes; Sara Granja; Sandra I Anjo; Fátima Baltazar; Bruno Manadas; António J Salgado; Bruno M Costa
Journal:  J Transl Med       Date:  2017-10-02       Impact factor: 5.531

5.  Metalloproteinases ADAM10 and ADAM17 Mediate Migration and Differentiation in Glioblastoma Sphere-Forming Cells.

Authors:  Elodie J Siney; Alexander Holden; Elizabeth Casselden; Harry Bulstrode; Gareth J Thomas; Sandrine Willaime-Morawek
Journal:  Mol Neurobiol       Date:  2016-08-19       Impact factor: 5.590

6.  Enhancing α-secretase Processing for Alzheimer's Disease-A View on SFRP1.

Authors:  Bor Luen Tang
Journal:  Brain Sci       Date:  2020-02-22

7.  CXCL16 Promotes Gastric Cancer Tumorigenesis via ADAM10-Dependent CXCL16/CXCR6 Axis and Activates Akt and MAPK Signaling Pathways.

Authors:  Jing Han; Runjia Fu; Cong Chen; Xiaojing Cheng; Ting Guo; Longtao Huangfu; Xiaomei Li; Hong Du; Xiaofang Xing; Jiafu Ji
Journal:  Int J Biol Sci       Date:  2021-07-05       Impact factor: 6.580

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.